Patent · US Active

Combination therapy of her expressing tumors

US8163287B2 · kind B2 · utility

32Cited by
48References
45Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 19, 2006
Grant dateApr 24, 2012
Priority date
Expiry dateDec 7, 2029

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/76
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.